Market Overview

UPDATE: Bank of America Raises PO to $40 on Integra Lifesciences

Related IART
FDA OKs Integra's Camino Flex Ventricular Catheter - Analyst Blog
Integra LifeSciences Introduces Wound Matrix - Analyst Blog

Bank of America Merrill Lynch reiterates a Neutral rating on Integra Lifesciences (NASDAQ: IART) and raises its price objective from $36 to $40.

Bank of America Merrill Lynch comments, “Raising PO to $40 We are raising our PO on IART to $40 from $36 primarily due to the recent signs of stabilization and/or strength in IART's most important orthopedic growth markets (extremities/spine) that we have documented in recent notes on Biomet and ZMH. Additionally, IART, like many US-focused small cap device names, would benefit in a disproportionate way if the Supreme Court declares President Obama's healthcare reform law unconstitutional this week (a decision is expected Thursday 6/28).”

Integra Lifesciences closed at $35.74 yesterday.

Posted-In: Bank of America Barack ObamaAnalyst Color News Politics Price Target Legal Analyst Ratings General

 

Most Popular

Related Articles (IART)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free